GenScript is constructing a new 30,000 square foot facility to support the manufacturing of protein and gene platforms for the Asia-Pacific region.
A groundbreaking ceremony at the site was attended by the country’s Minister of State, Alvin Tan, and the Senior Vice President of the Singapore Economic Development Board, Goh Wan Yee. During the ceremony, GenScript and Diagnostics Development (DxD) Hub signed a Memorandum of Understanding to explore building more manufacturing capabilities in Singapore.
“This is an important milestone for us as we strengthen our presence in the dynamic and innovative Asia-Pacific ecosystem in Singapore. The new manufacturing facility will be a regional hub of innovation and excellence in Asia-Pacific and will increase the productivity of custom protein manufacturing,” said Johnson Wang, president of GenScript’s Asia Division. “With the new manufacturing facility, we will be able to foster closer collaboration with partners, research institutes and biopharmaceutical companies throughout the Asia-Pacific region.”
The site could be expanded in the future to strengthen other units and support cell and gene therapy manufacturing in the region.
In late 2021, GenScript, Suzhou Abogen and Walvax Biotechnology announced that the three companies would collaborate on a Covid-19 mRNA vaccine project dubbed ABO-O28M.
Massachusetts CMO Adds New Development Capabilities to Accelerate Time to Market and Reduce Risk
A small-town manufacturer in western Massachusetts has added formulation, freeze-drying and method development capabilities to its operations, the company announced.
Berkshire Sterile will now offer first-in-man formulation development, supply materials for preclinical studies, and perform research-level stability studies at its Lee, MA facility. The company will use materials more compliant with the future of GMP manufacturing for formulation development.
“We are very experienced in complex formulations and unique filling programs. However, we have found that many companies we work with do not have their formulations fully developed or optimized,” CTO and co-founder Andrea Wagner said in a statement. “We have expanded our team to add these development activities to better support our customers and provide new offerings to future customers as well. We can get our customers to production faster and with greater confidence in their success by doing their development in-house. »
The new services will help reduce business delays, reduce risk and facilitate future scaling.
At the end of January, BSM promoted Xufeng Sun to vice president of formulation and technology transfer, after about two years with the company.